QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross-sectional analysis of the randomized AGMT 02 study

Heinz Ludwig, Thomas Melchardt (Co-author), Ilvy Schweitzer, Siegfried Sormann, Martin Schreder, Johannes Andel, Bernd Hartmann, Niklas Zojer, Laurenz Schoeffmann, Eberhard Gunsilius, Klaus Podar, Alexander Egle (Co-author), Wolfgang Willenbacher, Ewald Woell, Reinhard Ruckser, Boris Bozic, Maria-Theresa Krauth, Andreas Petzer, Clemens Schmitt, Sigrid Machherndl-SpandlHermine Agis, Michael Fillitz, Song-Yau Wang, Stefan Knop (Co-author), Richard Greil (Last author)

Research output: Contribution to journalOriginal Article (Journal)peer-review

Abstract

Understanding the impact of induction and maintenance therapy on patients' quality of life (QoL) is important for treatment selection. This study aims to compare patient-reported QoL between patients treated with KTd or KRd induction therapy and K maintenance therapy or observation. QoL was assessed using the EORTC QOL-C 30 and QOL-MY20 questionnaires in the AGMT-02 study, in which 123 patients with newly diagnosed transplant ineligible multiple myeloma were randomized to nine cycles of either KTd or KRd induction therapy, followed by 12 cycles of K maintenance therapy, or observation. Longitudinal assessments showed statistically significant improvements in global health-related QoL, various disease symptoms and pain for both treatment regimens. KTd improved insomnia and fatigue, and KRd improved physical functioning. Cross-sectional comparisons indicated a "slight" superiority of KTd over KRd in several scales, with the exception of higher neuropathy scores with KTd. During maintenance, longitudinal comparisons showed no statistically significant changes. Cross-sectional comparisons revealed a "slight" improvement in cognitive functioning during carfilzomib therapy, but a worsening in most other QoL scales. Induction therapy led to improvements in most QoL items, while maintenance therapy with K maintenance was associated with "slight" or "moderate" impairments in several QoL scales compared with the observation group.
Original languageEnglish
Number of pages11
JournalEJHAEM
Early online dateMay 2024
DOIs
Publication statusPublished - 17 May 2024

Keywords

  • Carfilzomib
  • Lenalidomide
  • Multiple myeloma
  • Quality of life
  • Thalidomide

Fingerprint

Dive into the research topics of 'QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross-sectional analysis of the randomized AGMT 02 study'. Together they form a unique fingerprint.

Cite this